Epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years.

Chin Med J (Engl) · 2025 · PMC11970819 · PMID 39994836

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

[ 89 ] The first RCT assessing the safety and efficacy of ACT found that CD patients receiving a combination therapy of natalizumab and IFX showed a trend toward higher rates of clinical remission over a 32-week follow-up period than those receiving IFX monotherapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.